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Hydroxyurea prevents arterial and late
venous thrombotic recurrences in patients
with myeloproliferative neoplasms but fails
in the splanchnic venous district. Pooled
analysis of 1500 cases
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Abstract
We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous thrombosis (935/565),
pooling three independent cohorts previously reported. Long-term treatment with antiplatelet drugs or vitamin K-
antagonists (VKA) was given to 1391 (92.7%) patients; 975 (65%) patients received hydroxyurea (HU). We recorded 348
recurrences (venous in 142 cases) over 6075 patient-years, with an incidence rate of 5.7 per 100 pt-years (95% CI
5.1–6.4). The site of the first thrombosis predicted the site of recurrence. Independent factors influencing the rate of
novel arterial thrombosis were HU (HR 0.67, 95% CI 0.46–0.98), antiplatelet treatment (HR 0.54, 95% CI 0.35–0.82), and
VKA (HR 0.58, 95% CI 0.35–0.96). On the contrary, the recurrence of venous thromboses was significantly diminished
only by VKA (HR 0.60, 95% CI 0.37–0.95), while HU prevented late but not early recurrences after venous thrombosis at
common sites. Of note, we failed to demonstrate a positive effect of HU in the prevention of recurrent splanchnic vein
thrombosis. In conclusion, in MPN patients, HU plays a role in the prevention of arterial thrombosis, together with
aspirin and VKA, whereas its action in the prevention of recurrent venous thrombosis is uncertain. Such findings call for
future studies to optimize and personalize secondary prophylaxis after MPN-related thrombosis.
Introduction
The principal burden of illness in patients with
Philadelphia-negative myeloproliferative neoplasms
(MPN) is arterial thrombosis and venous thromboembo-
lism (VTE), which can occur since the very early stages of
disease and complicate the course of the follow-up with
an elevated rate constant over time1; on the other hand,
fibrotic or leukemic transformation are late complica-
tions. The incidence of either arterial thrombosis or VTE
is approximately tenfold higher than in the general
population2,3.
In MPN patients having experienced a first thrombosis,
the rate of recurrence is 4.8% patient-years after an
ischemic cerebrovascular event4 and 6–7.6% patient-years
after a venous event4–8. Prevention of thrombosis or re-
thrombosis is the major goal of care in MPN patients.
However, the efficacy of conventional strategies of sec-
ondary antithrombotic prophylaxis is unsatisfactory either
using antiplatelet agents after arterial events4,5 or vitamin
K-antagonists (VKA) after venous events6–8.
Three randomized clinical trials demonstrated the effi-
cacy of hydroxyurea (HU) in reducing the rate of
thrombosis in high-risk patients with essential
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thrombocythemia (ET)9–11; moreover, in a recent reap-
praisal of the European Collaborative Low-dose aspirin
(ECLAP) study, high-risk patients with polycythemia vera
(PV) resulted better protected by HU than phlebotomies
alone12. However, there is some evidence that the benefit
of HU is somewhat vessel site-related. In the PT-1 trial,
the HU arm had an excess of venous thromboses in
respect to the anagrelide arm10. Moreover, in a retro-
spective cohort of 494 MPN patients with previous
thrombosis, HU was effective in preventing recurrences in
patients with a first arterial event but not in those with a
first venous event5. On the other hand, in a retrospective
cohort of 597 MPN patients with ischemic stroke or TIA,
HU resulted in a strong protective factor for the devel-
opment of recurrent ischemic stroke4. Finally, we recently
investigated more thoroughly the PV patients recruited in
the ECLAP cohort, showing that HU was more effective
than phlebotomy in preventing either first or recurrent
arterial thromboses, but not venous thromboses13.
To investigate further on whether different antith-
rombotic or cytoreductive agents can play different roles
in the prevention of recurrent thrombosis in MPN
patients, we took advantage of several large databases
built in the last decade, pooling a cohort of 1500 patients
with MPN and previous thrombosis.
Patients and methods
In the last decade, three studies specifically aimed to
investigate the rate of recurrent thrombosis, and the
effects of secondary prophylactic treatments have been
conducted by the Italian Network on MPN. The details of
the recruitment criteria have been reported else-
where4,5,7,8. Briefly, the participants were asked to identify,
among all consecutive patients with MPN referred to their
centers, those who had suffered from thrombosis. The
index event had to be concurrent with MPN diagnosis, or
in 2 years before, or occurring during a previously diag-
nosed MPN disease. The major thrombotic events of
interest were ischemic stroke, transient ischemic attacks,
acute myocardial infarction, unstable angina pectoris,
peripheral arterial thrombosis, retinal artery or vein
occlusion, deep venous thrombosis (including thrombosis
of cerebral and splanchnic veins), and pulmonary embo-
lism. Acute coronary syndrome encompassed acute
myocardial infarction as well as unstable angina pectoris.
Cerebrovascular disease encompassed ischemic stroke as
well as transient ischemic attacks. Splanchnic venous
thrombosis included occlusion of hepatic, portal, mesen-
teric, and splenic veins. The diagnosis of a first or
recurrent major thrombotic event was accepted only if
objectively proven as previously described4,5,7,8. For each
patient, the following information was recorded: demo-
graphic data, WHO diagnosis, location of thrombosis,
method of objective diagnosis, presence of microvascular
disturbances or constitutional symptoms, mutational
profile, results of the laboratory investigation for throm-
bophilia, full blood count at diagnosis and at thrombosis,
and the presence of constitutional risk factors, including
history of previous thrombosis before the index event,
smoking habit, hypertension and dyslipidemia, diabetes,
and risk factors for cardiogenic embolism or vascular
embolism. Moreover, the presence of circumstantial risk
factors at the time of an episode of VTE, such as surgery,
pregnancy, puerperium, oral contraceptive intake, hor-
mone replacement therapy, trauma, leg cast and pro-
longed bed immobilization, and long travel, was also
recorded; in the absence of these risk factors, VTE was
considered unprovoked. Finally, data regarding cytor-
eductive or antithrombotic treatment after thrombosis,
the duration of the treatment, and the reasons for dis-
continuation of the therapy were recorded. Major bleed-
ing events were also recorded4,5,7,8.
The first study recruited MPN patients consecutively
diagnosed from January 1985 to December 20055,
whereas the other two studies recruited patients with a
diagnosis of MPN carried out from January 20054,7,8.
However, a careful comparison of the database checked
the patients diagnosed in 2005, and no patient resulted to
be included twice.
The first study was conducted in the frame of the
GIMEMA (Gruppo Italiano Malattie Ematologiche del-
l’Adulto) and included 494 patients with PV or ET and
either arterial (n= 338) or venous thrombosis (n= 156);
27 of them had a diagnosis of superficial vein thrombosis
and were excluded from further analysis5. The other two
studies were conducted in the frame of the ELN (Eur-
opean LeukemiaNet). One recruited 436 MPN patients
with VTE, including 206 patients with VTE at common
sites7, 181 patients with splanchnic vein thrombosis8, and
35 patients with cerebral vein thrombosis so far unpub-
lished. Finally, the second ELN study recruited 597 MPN
patients with TIA (n= 270) or ischemic stroke (n= 327)4.
The three studies were designed by the same principal
investigators (VDS and TB) employing the same criteria
of inclusion over time, so that the individual patient data
from the original database were considered eligible to be
combined across the studies.
Statistical methods
Differences in proportions were estimated by the Fish-
er’s exact test (statistical significance threshold set at p <
0.05). The annual incidence rate of an event that occurred
during the follow-up was calculated by dividing the
number of events by the total number of patient-years.
The probability of recurrence as a function of time was
estimated using the Kaplan–Meier method by analyzing
the interval between the initial thrombosis and a recurrent
thrombotic event (uncensored observations), or the
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duration of time until death, or the time elapsed until the
patient’s final visit to the center (censored observations).
The probability of recurrence was compared between the
groups using the log-rank test (statistical significance
threshold set at p < 0.05), and the relative risk of recur-
rence was estimated as a hazard ratio (HR) with a 95%
confidence interval using a Cox proportional hazards
regression model. The HR was adjusted taking recurrence
as the dependent variable and with covariates being sex,
age at the time of the index thrombotic event (less than or
more than 60 years old), type of index thrombosis (arterial
or venous), and type of treatment after thrombosis:
antithrombotic prophylaxis with antiplatelet agents or
long-term oral anticoagulation, cytoreduction by HU, or
any type of other pharmacological cytoreductive treat-
ment. Statistical analyses were performed using MedCalc
Statistical Software version 17.2 (MedCalc Software bvba,
Ostend, Belgium; http://www.medcalc.org; 2017).
Results
Patient characteristics and rate of recurrent thrombosis
The clinical and laboratory features of the pooled
cohort are reported in Table 1. Most patients were
affected by PV or ET. About two-thirds of the cohort
consisted of patients with arterial thrombosis; the clinical
manifestations more represented were cerebrovascular
diseases, deep vein thrombosis of the legs with or without
pulmonary embolism, and splanchnic vein thrombosis,
mirroring the patho-epidemiology of MPN1,2. Cytor-
eduction (mostly with HU) and/or antithrombotic treat-
ment was given to 97.4% of the patients. The dose of HU
was given according to the current medical practice, i.e.,
aimed to control hypercythemia, reducing the cell count
within the normal range and/or to recommended values
(e.g., Hct ≤ 0.45 in PV patients). The incidence rate of
recurrent thrombosis was 5.7% patient-years, as expected
from previous estimates3–7, with no significant difference
between the rate of recurrent thrombosis after a first
arterial event or a first venous event (p= 0.67) (Table 2).
However, the site of the first thrombosis was a strong
predictor of the site of recurrence, confirming previous
findings4,5. Among the patients who had a novel throm-
bosis after the index event, the coincidental involvement
of the same arterial or venous district of the first throm-
bosis occurred in 77.2% of those with an initial arterial
thrombosis (p < 0.0001 vs. the rate of novel venous
thrombosis) and in 71.8% of those with an initial venous
thrombosis (p < 0.0001 vs. the rate of novel arterial
thrombosis). After adjustment for sex, age, and antith-
rombotic or cytoreductive treatment, the risk of arterial or
venous recurrence was significantly higher in patients
having had a first arterial thrombosis (HR 2.94, 95% CI
1.92–4.51, p < 0.0001) or a first venous thrombosis (HR
3.30; 95% CI 2.18–5.01, p < 0.0001), respectively.
Overall efficacy of treatments in preventing recurrent
thrombosis
A multivariable analysis of the effect of treatments in
the overall cohort showed a significantly protective effect
either of antiplatelet agents or VKA treatment, with a
decreased rate of re-thrombosis by 42%. On the other
hand, HU was associated with a reduced risk of only
borderline statistical significance (Table 3). However,
analyzing the arterial and venous thrombotic outcomes
separately, after adjustment for the site of the first
thrombosis (arterial vs. venous), antiplatelet and VKA
treatment retained their statistical significance in pre-
venting arterial recurrences but also HU resulted in an
Table 1 Clinical features of the cohort at the index
thrombosis (N= 1500)






Age at thrombosis—median (range) 65 (19–90)
>= 60 years 848 (56.5%)
Type of index thrombosis
Arterial thrombosis (N= 935)
Acute coronary syndrome 107 (7.1%)
TIA 302 (20.1%)
Ischemic stroke 486 (32.5%)
Other arterial thromboses 40 (2.7%)
Venous thrombosis (N= 565)
DVT of the legs and/or pulmonary embolism 293 (19.5%)
Budd–Chiari syndrome 38 (2.5%)
Portal–mesenteric venous thrombosis 180 (12.0%)
Cerebral vein thrombosis 40 (2.7%)
Other venous thromboses 14 (0.9%)
Aspirin or other antiplatelet agents 892 (59.4%)
Oral anticoagulation (VKA, DOACs) +/− ASA 499 (33.2%)
Hydroxyurea 975 (65.0%)
Hydroxyurea alone 55 (3.7%)
Hydroxyurea+ antiplatelet agents 589 (39.3%)
Hydroxyurea+ oral anticoagulation 290 (19.3%)
Hydroxyurea+ other regimens* 41 (2.7%)
Other cytoreductive drugs 257 (17.1%)
*s.c. heparin, VKA/DOACs+ antiplatelet agents, and dual antiplatelet treatment
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independent protective factor. On the contrary, anti-
platelet agents and HU were less effective in preventing
novel venous thromboses (Table 3). Finally, cytoreductive
drugs other than HU (i.e., anagrelide, interferon, pipo-
broman, busulfan, and ruxolitinib) did not affect the rate
of recurrent thrombotic events.
Vessel site-related efficacy of treatments in preventing
recurrent thrombosis
The multivariable analysis limited to the patients with
first arterial thrombosis confirmed that recurrent arterial
thrombosis was prevented by antiplatelet agents (HR 0.49,
95% CI 0.31–0.78, p= 0.003) and by HU (HR 0.64, 95% CI
0.42–0.98, p= 0.04) and only partially by VKA (HR 0.53,
95% CI 0.27–1.04, p= 0.06); on the contrary, in patients
with the first venous thrombosis, the venous recurrences
were more prevented by VKA (HR 0.57, 95% CI
0.35–0.94) than by antiplatelet agents (0.71, 95% CI
0.41–1.24, p= 0.24) or HU (HR 0.75, 95% CI 0.46–1.23, p
= 0.26).
Notably, analyzing patients with VTE according to the
site of thrombosis, HU was confirmed to be without a
significant effect on the rate of either recurrent throm-
bosis or recurrent VTE in 218 patients with splanchnic
vein thrombosis (HR 0.81, 95% CI 0.39–1.65, p= 0.56,
and HR 0.92, 95% CI 0.40–2.13, p= 0.85, respectively),
after adjustment for age, sex, antiplatelet treatment, VKA
treatment, and cytoreductive agents other than HU. On
the opposite, when analyzing the 293 patients with VTE at
common sites (i.e., deep vein thrombosis of the legs and/
or pulmonary embolism), HU was found significantly
effective in reducing the rate of either recurrent throm-
bosis or recurrent VTE (HR 0.56, 95% CI 0.32–0.99, p=
0.04, and HR 0.50, 95% CI 0.26–0.95, p= 0.03, respec-
tively). Such findings were not substantially modified after
adjustment of the model for the white blood cell count at
diagnosis (data not shown).
Figure 1 shows the favorable cumulative incidence of
recurrent thrombosis after the first arterial event in
patients receiving HU and no effect of this drug after the
first splanchnic venous thrombosis. No significant
advantage was observed in prevention of arterial
Table 2 Incidence of thrombosis and bleeding after the
index event
Events, n (%) Incidence rate % pt-years
(95% CI)
After a first thrombosis
(N= 1500, total patient-years= 6075)
Thrombotic events 348 (23.2%) 5.7 (5.1–6.4)
Major bleeding 77 (5.1%) 1.3 (1.0–1.6)
After first arterial thrombosis
(N= 935, total patient-years= 3907)
Thrombotic events 220 (23.5%) 5.6 (4.9–6.4)
Arterial thrombosis 170 (18.2%) 4.3 (3.7–5.0)
Venous thrombosis 50 (5.3%) 1.3 (0.9–1.7)
Major bleeding 44 (4.7%) 1.1 (0.8–1.5)
After a first venous thrombosis
(N= 565, total patient-years= 2168)
Thrombotic events 128 (22.6%) 5.9 (4.9–7.0)
Arterial thrombosis 36 (6.3%) 1.7 (1.2–2.3)
Venous thrombosis 92 (16.3%) 4.2 (3.4–5.2)
Major bleeding 33 (5.8%) 1.5 (1.0–2.1)
Table 3 Effect of long-term treatments on the risk of recurrences after the index thrombosis in the entire patient cohort
(multivariable analysis).
Overall recurrent
thromboses (HR, 95% CI)
Arterial recurrent
thrombosis (HR, 95% CI)*
p Venous recurrent
thrombosis (HR, 95% CI)*
p
Age > 60 years 1.23 (0.99–1.52) 0.06 1.18 (0.89–1.57) 0.23 1.28 (0.91–1.79) 0.15
Male sex 0.94 (0.76–1.17) 0.60 0.97 (0.73–1.28) 0.99 0.91 (0.65–1.28) 0.61
Antiplatelet treatment 0.58 (0.43–0.79) 0.0005 0.54 (0.35–0.82) 0.003 0.64 (0.40–1.03) 0.07
Oral anticoagulation (VKA or
DOACs)
0.58 (0.41–0.81) 0.001 0.58 (0.35–0.96) 0.03 0.60 (0.37–0.95) 0.03
Hydroxyurea 0.75 (0.57–1.00) 0.05 0.67 (0.46–0.98) 0.04 0.87 (0.56–1.33) 0.52
Cytoreduction with agents other
than hydroxyurea#
1.04 (0.74–1.45) 0.80 0.94 (0.61–1.46) 0.80 1.22 (0.72–2.04) 0.44
HR hazard ratio
*Multivariable analysis adjusted for the arterial or venous site of the first thrombosis
#Anagrelide, interferon, pipobroman, busulfan, and ruxolitinib
Bold values are those with statistical significance
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recurrences in the patients with the first arterial throm-
bosis, taking both HU and antiplatelet treatment over
those taking only HU (HR 0.57, 95% CI 0.17–1.29, p=
0.14) or only antiplatelet treatment (HR 0.82, 95% CI
0.52–1.17, p= 0.26); on the other hand, no significant
advantage was observed in prevention of venous recur-
rences in the patients with the first venous thrombosis
taking both HU and VKA over those taking only HU (HR
0.76, 95% CI 0.30–1.82, p= 0.51) or only VKA (HR 0.92,
95% CI 0.55–1.57, p= 0.79). The probability of
recurrence-free survival after venous VTE at common
sites was not seen in the first 5 years of HU treatment (HR
at 5 years 0.71, 95% CI 0.36–1.27, for HU vs. no HU, p=
0.23), while a positive effect was documented in the 76
patients who were exposed to this drug for more than 5
years. In these cases, recurrent VTE occurred in 1/48
patients on HU and in 7/28 patients not receiving this
drug (HR 0.08, 95% CI 0.02–0.46, p= 0.0028). The
patients with a follow-up shorter or longer than 5 years
did not differ as regards the rate of treatment with HU
only (p= 0.86), HU and VKA (p= 0.35), and VKA only (p
= 0.52).
Discussion
We confirmed that in MPN patients, the rate of
recurrent thrombosis is high and occurs in 5.7% patient-
years in spite of secondary prophylaxis administered by
specialized centers4–8. Cytoreductive treatment with HU
is strongly recommended as first-line therapy in high-risk
patients, particularly in those with a history of thrombo-
sis14. However, whether HU has a different protective role
on the prevention of arterial or venous thrombosis is
uncertain and was addressed in a limited number of
studies5,10,13.
In the present study, involving a huge number of 1500
patients with arterial or venous events, multivariable
analysis demonstrated a different protective action of HU
on recurrences according to the district in which the first
episode of thrombosis occurred. We confirmed here that
HU in association with both antiplatelet and VKA treat-
ment, was able to reduce the rate of recurrent arterial
thrombosis, but we did not show a significant action of
the drug in the prevention of total recurrent venous
thrombosis after thrombosis at common sites and
splanchnic vein thrombosis.
Although venous and arterial thrombotic disease have
been historically regarded as distinct diseases with dif-
fering etiologies, these two classes of thrombotic events
share common characteristics. Both hypercoagulability
and inflammation contribute to the development of
arterial and venous thrombi, and risk factors for the two
diseases are not altogether dissimilar15. However, the
magnitude of arterial risk associated with a previous
arterial thrombosis is not as high as that associated with a
previous venous thrombosis and vice versa, so that the
etiology of these two thrombotic diseases may be distinct.
Arterial and venous thrombosis can develop through
different cellular and plasma pathways16, so that it is not
Fig. 1 Effect of hydroxyurea (HU) on the cumulative incidence of
recurrent arterial thrombosis after an arterial event (top panel) and of
recurrent venous thrombosis after a venous thromboembolism (VTE)
at common sites (i.e., legs and pulmonary vessels) (middle panel) or
after a splanchnic vein thrombosis (SVT) (bottom panel)
De Stefano et al. Blood Cancer Journal           (2018) 8:112 Page 5 of 7
Blood Cancer Journal
surprising that drugs with different targets can achieve
different results in preventing thrombosis in different
vessel districts. The prevention of arterial recurrences
mediated by HU may be due to myelosuppressive activity
but also to the direct antithrombotic action on poly-
morphonuclear leukocytes function and their interaction
with platelets17. The importance of leukocytes in the
pathophysiology of arterial thrombosis is well established
in non-MPN individuals18,19. Accordingly, leukocytosis
has been reported as a potential determinant for myo-
cardial infarction both in PV20 and in ET21,22 but not for
VTE20–22.
On the other hand, activation of the coagulation system
is the primary cause of venous thrombosis, and precedes
platelet activation and aggregation. This may explain why
HU had a limited activity in preventing recurrences of
common venous thromboses in MPN patients, while
anticoagulation therapy independently resulted as a pro-
tective drug reducing the rate of recurrences, as in the
non-MPN population. In the latter non-MPN subjects,
the risk of recurrence after unprovoked VTE is the highest
during the first 5 years after discontinuation of antic-
oagulation and then declined, but never completely dis-
appeared23. In our study, the efficacy of HU in patients
with VTE at common sites was not demonstrated in the
first 5 years after the incident event, suggesting that in this
period, the cellular component of venous thrombogenesis
is not as important as plasma hypercoagulability, which is
well controlled by oral anticoagulants. Subsequently, HU
showed a strong positive effect, indicating an advantage in
the control of myeloproliferation.
Of note, we failed to show a positive action of HU in
preventing recurrences after the first incident episode of
splanchnic vein thrombosis. The reason of this finding is
difficult to explain; it could be speculated that in patients
with splanchnic vein thrombosis, hypercythemia is less
frequent24, so that cytoreduction in this setting could be
less crucial than otherwise. Moreover, given the unique
environment of the splanchnic venous system, it is likely
that the mechanisms of SVT formation differ from the
mechanisms of arterial and VTE at common sites. Liver
endothelial cells isolated from two patients with
Budd–Chiari syndrome25 and spleen endothelial cells26
have been found to carry the JAK2 V617 mutation, so that
aberrant endothelial cells may eventually contribute to
SVT pathogenesis. Therefore, the occurrence of SVT,
occurring either as the heralding presentation of MPN or
as a complication during the course of the disease, poses
an important clinical decision on the use of cytoreduction.
We suggest to prescribe HU only in the presence of
hypercythemia or in the case of progressive disease.
In our analysis, VKA were significantly effective in
reducing the rate of venous thrombotic recurrences by
40%. This reduction in risk is comparable with the results
obtained in the prevention of recurrent VTE in the non-
MPN population27. However, given the different risk
baselines in the MPN and non-MPN patients, the abso-
lute incidence rate of recurrent venous thrombosis in
MPN patients remains higher than that observed in non-
MPN patients treated with VKA, as previously reported7.
Finally, in the patients treated with cytoreductive drugs
other than HU (i.e., anagrelide, busulfan, pipobroman,
interferon, and ruxolitinib), we did not show any antith-
rombotic efficacy in terms of reduction of recurrences.
However, this finding should be taken with caution,
because the number of treated patients for each drug is
likely not enough powered.
In conclusion, although our study has limitations due to
the retrospective nature, this series of 1500 MPN patients
with incident index thrombosis is the largest ever repor-
ted, so that statistical power is adequate. The different
effects of HU on the protection of arterial or venous
vessels likely mirror the different pathogenetic mechan-
isms involved in thrombosis of different districts. The
results obtained by VKA for secondary prophylaxis of
recurrent VTE although significant are not entirely
satisfactory. Overall, we conclude that our therapy
armamentarium to prevent arterial and particularly
venous recurrences in MPN is suboptimal, and future
studies to optimize and personalize the secondary phar-
macological prophylaxis are urgently warranted.
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